GFAP and myeloid sarcoma: Indeed, an increase of GFAP was also found in the CSF of MS patients, in particular in secondary progressive MS patients which is well in line with previous observations [37], [38] and adds GFAP to other markers like neurofilament or nitric oxide metabolites that were also shown to correlate with disability or disease progression [42], [43].